Last $59.33 USD
Change Today +0.51 / 0.87%
Volume 409.0K
HSP On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 11:10 AM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

hospira inc (HSP) Snapshot

Open
$59.00
Previous Close
$58.82
Day High
$59.59
Day Low
$58.82
52 Week High
11/18/14 - $59.78
52 Week Low
11/25/13 - $39.05
Market Cap
10.1B
Average Volume 10 Days
969.6K
EPS TTM
$2.16
Shares Outstanding
169.2M
EX-Date
--
P/E TM
27.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for HOSPIRA INC (HSP)

hospira inc (HSP) Details

Hospira, Inc. provides injectable pharmaceutical drugs and infusion technologies to develop, manufacture, distribute, and market products worldwide. The company operates through Americas, EMEA, and APAC segments. It provides specialty injectable pharmaceuticals, which include approximately 200 injectable generic drugs in multiple dosages and formulations; and proprietary specialty injectables, such as Precedex, a proprietary drug for sedation. The company’s specialty injectable pharmaceuticals also comprises Biosimilars that include Retacrit, a biosimilar erythropoietin, which is primarily used in the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim used for the treatment of low white blood cells in patients who have received a chemotherapeutic agent; and Inflectra, a biosimilar infliximab for the treatment of inflammatory conditions, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and psoriasis. In addition, it offers medication management products, including infusion pumps and dedicated administration sets; Hospira MedNet safety software system and related services; software applications and devices that support point-of-care medication administration; gravity administration sets; and other device products. Further, the company provides intravenous solutions and nutritional products; and contract manufacturing services, as well as develops proprietary pharmaceutical products, such as Dyloject, a post-operative pain management drug. It serves hospitals and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company has collaborative arrangements with Bioceuticals Arzneimittel AG to license and market Retacrit; and Q Core Medical, Ltd to market and distribute Sapphire, a multi-therapy infusion system. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.

17,000 Employees
Last Reported Date: 02/12/14
Founded in 2003

hospira inc (HSP) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $1.0M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $464.7K
Senior Vice President of Operations
Total Annual Compensation: $432.5K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $444.6K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $429.8K
Compensation as of Fiscal Year 2013.

hospira inc (HSP) Key Developments

Hospira, Inc. Mourns Passing of Founding Board Member Connie R. Curran

The board of directors and employees of Hospira Inc. expressed their deepest sorrow over the loss of Connie R. Curran one of the company's founding board members.

Hospira Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Full Year of Fiscal 2014

Hospira Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company announced net sales of $1,150.6 million compared to $1,008.2 million for the same period a year ago. Income from operations was $227.5 million compared to $29.8 million for the same period a year ago. Income before income taxes was $204.0 million compared to loss before income taxes of $32.5 million for the same period a year ago. Net income was $158.6 million compared to $1.9 million for the same period a year ago. Earnings per common share, diluted were $0.92 compared to $0.01 for the same period a year ago. Adjusted income from operations was $192.6 million compared to $122.0 million for the same period a year ago. Adjusted net income was $127.5 million compared to $84.5 million for the same period a year ago. Adjusted diluted earnings per share were $0.74 compared to $0.51 for the same period a year ago. Net sales benefited from the continued strong global sales of Specialty Injectable Pharmaceuticals (SIP) products. Adjusted income from operations increased primarily reflects the impact of improved pricing and increased volume in sales of the company's SIP products, which were partially offset by higher Research and development expenses, as well as higher Selling, general and administrative expenses. For the nine months, the company announced net sales of $3,337.2 million compared to $2,918.4 million for the same period a year ago. Income from operations was $426.6 million compared to loss from operations of $36.6 million for the same period a year ago. Income before income taxes was $366.3 million compared to loss before income taxes of $150.7 million for the same period a year ago. Net income was $297.4 million or $1.75 per diluted share compared to net loss of $41.8 million or $0.25 per diluted share for the same period a year ago. Adjusted net sales were $3,337.2 million compared to $3,022.7 million for the same period a year ago. Adjusted income from operations was $523.4 million compared to $349.6 million for the same period a year ago. Adjusted net income was $351.3 million compared to $262.7 million for the same period a year ago. Adjusted diluted earnings per share were $2.06 compared to $1.58 for the same period a year ago. Net cash provided by operating activities was $334.3 million compared to $61.5 million for the same period a year ago, driven primarily by the improved earnings. Capital expenditures (including instruments placed with or leased to customers) were $279.0 million compared to $248.5 million for the same period a year ago. The increase reflects planned spending related to new Vizag, India facility, as well as other plant modernization initiatives. Purchases of intangibles and other investments were $35.2 million compared to $12.2 million for the same period a year ago. The company revised earnings guidance for the full year of fiscal 2014. Based on the company's assumptions regarding the impact in the fourth quarter of the genericization of Precedex, The company now expects net sales growth for full-year 2014 to range between 8.5% and 9.5% on a constant-currency basis, with minimal impact from foreign currency. The company is now projecting adjusted diluted earnings per share for 2014 to range between $2.40 and $2.50, the upper end of the prior range. Diluted earnings per share GAAP expected to be between $1.80 and $1.90. The company is updating its guidance for full-year 2014 cash flow from operations, which it now expects to range between $425 million and $475 million. Capital expenditure projections remain in a range between $375 million and $425 million. The company continues to expect depreciation and amortization to range between $225 million and $275 million.

Hospira, Inc. Announces U.S. Launch of Generic Paricalcitol Injection

Hospira Inc. announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration (FDA) approval of paricalcitol on Oct. 21 and launched the product November 1, 2014. Hospira's paricalcitol - available in three multi-dose vial configurations - is approved for the prevention and treatment of secondary hyperparathyroidism associated with Stage 5 chronic kidney disease (CKD). Hyperparathyroidism contributes to the development of metabolic bone disease. Sterile use of multi-dose vials can reduce waste because the vial's entire contents can be utilized over time, as opposed to single-dose vials, which require clinicians to discard the unused volume of solution after drawing up the patient's specific dose. The current branded drug offers only one of three sizes as a multi-dose configuration. Hospira will offer multi-dose configurations in 5 mcg and 10 mcg vials of paricalcitol in a 5 mcg/mL concentration, and then 2 mcg vials of paricalcitol in a 2 mcg/mL concentration. These are the concentrations that customers have used for many years. Hospira's specialty injectable pharmaceuticals (SIP) offering includes approximately 200 generic injectable drugs in many dosages and formulations. In addition, many of its products are available in popular differentiated presentations, several of which are proprietary, such as ADD-Vantage(TM) drug delivery system and iSecure(TM) prefilled syringes. Therapeutic segments include analgesia, anesthesia, anti-infectives, cardiovascular, oncology, emergency and other areas. Hospira also has robust pipelines of both generic and biosimilar drugs.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HSP:US $59.33 USD +0.51

HSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CareFusion Corp $58.45 USD +0.20
Cintas Corp $72.45 USD +0.53
Grifols SA €35.84 EUR +0.025
Terumo Corp ¥2,715 JPY +31.00
Varian Medical Systems Inc $88.03 USD +0.28
View Industry Companies
 

Industry Analysis

HSP

Industry Average

Valuation HSP Industry Range
Price/Earnings 30.1x
Price/Sales 2.2x
Price/Book 3.0x
Price/Cash Flow 30.1x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOSPIRA INC, please visit www.hospira.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.